AstraZeneca PLC
Develops and commercialises prescription medicines across oncology, cardiovascular, respiratory, immunology, vaccines, and rare disease therapies.
As of Aug 28, 2026
Summary
AstraZeneca is a global pharmaceutical and biotech company traded on the London Stock Exchange with a market capitalisation of £186 billion. The stock is trading at 11,970p and shows a neutral technical bias, having retreated 5.3 percent over the past month despite posting a gain of 2.7 percent over the past year.
Price history
As of Aug 28, 2026
Performance
+0.00%
-2.21%
-5.27%
-8.81%
-11.71%
+2.74%
As of Aug 28, 2026
Technical indicators
- 45.2
- 78.98Bullish
- 50: 12696.39 · 200: 13610.35Bearish
- 11,720p / 12,476p
Technical Bias
AstraZeneca's technical indicators are mixed: momentum is building with MACD in bullish territory, but the price sits below both its 50-day and 200-day moving averages, which lean bearish, whilst RSI sits neutral around midpoint. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Aug 28, 2026
Fundamentals
- £186B
- 24.33
- 4.92p
- 17.02%
- +6.4%
- £8.67B
- 0.21
- 9,827p – 15,468p
- 1.97%
- Aug 6, 2026
- Oct 30, 2026 (61 days)
As of Aug 29, 2026
Upcoming catalysts
- Earnings report
As of Aug 29, 2026
Latest news
As of Aug 29, 2026
MonkeyTrade's Take on AstraZeneca PLC
Short-term outlook
The short-term picture leans bearish, with AstraZeneca sitting below both its 50-day (12,696.39p) and 200-day (13,610.35p) averages after a 5.3% pullback over the past month. RSI at 45.2 is neutral, so there's no oversold bounce signal yet, and MACD's bullish reading hasn't translated into price strength. Watch 12,476p resistance for a shift higher, or 11,720p support for confirmation of further downside; no earnings catalyst is imminent, with the next report not due until October 2026.
Medium-term outlook
AstraZeneca's mix of steady 6.4% revenue growth, a solid 17% profit margin and a 2% dividend gives the medium-term case a defensive tilt, though a 24.33 P/E means the shares are priced for continued delivery rather than a discount. With the technical picture flat, the fundamentals lean modestly constructive over the coming quarters. A slowdown in revenue growth would be the key thing to change this view.
Key risks
- Clinical trial outcomes remain a swing factor, and the recent decision to ditch a lung cancer treatment trial shows that pipeline setbacks can happen even alongside positive Phase III results elsewhere.
- The stock trades well below its 52-week high of 15,468p at a current 11,970p, which may reflect the market pricing in some caution despite the string of positive trial headlines.
- A price-to-earnings ratio of 24.33 suggests investors are already paying a premium for growth, leaving less room for error if future trial data or revenue growth of +6.4% year-on-year were to disappoint.
- Heavy reliance on late-stage trial newsflow, as seen with TEZSPIRE and the lung cancer programmes, means sentiment can shift quickly on individual study results rather than on bro
About AstraZeneca PLC
AstraZeneca PLC is one of the world's largest pharmaceutical companies, listed on the London Stock Exchange under the ticker AZN. Operating in the healthcare sector within the drug manufacturers industry, the company develops and markets medicines across areas such as oncology, cardiovascular disease and respiratory conditions. With a market capitalisation of £186B, AstraZeneca sits among the heavyweight names on the LSE, reflecting its scale and standing within global pharmaceuticals.
The company's key figures give a sense of how the market currently views the business. A price-to-earnings ratio of 24.33 shows what investors are willing to pay for each pound of earnings, while a dividend yield of +2.0% indicates the income return shareholders receive relative to the share price. Together, these metrics offer a snapshot of AstraZeneca's valuation and income profile for those researching the stock.
How to trade AstraZeneca PLC
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.